TLR4 Synthetic Agonist
TLR4 agonists are compounds that activate innate immune pathways, enhancing the body’s response to vaccination. When integrated into adjuvant systems, they help optimize vaccine performance, enabling stronger, more durable, and targeted immune protection across a wide range of disease applications.
TECHNOLOGY PARTNERSHIP
Through its partnership with Inimmune Corporation, SPI Pharma offers INI-2002, a fully synthetic, GMP-grade TLR4 agonist. Available for licensing, this innovative molecule expands access to advanced adjuvant technologies, supporting the development of next-generation vaccines with reliable quality and commercial scalability.
Our Portfolio
INI-2002
INI-2002 is a novel, fully synthetic TLR4 agonist developed by Inimmune Corp, activates the innate immune response via TLR4 and drives downstream antigen-specific adaptive immune responses. Its unique structure, featuring amide substitutions, provides excellent chemical and thermal stability, making it highly suitable for advanced vaccine formulations.
In preclinical models, INI-2002 demonstrates comparable or superior performance to MPL as a vaccine adjuvant, while offering significantly improved chemical stability.
Key Advantages:
• Robust IP Protection and Available for Licensing
• Manufactured Under cGMP Conditions
• Attractive Pricing at Commercial Scale
• Excellent stability and versatile formulatability.
Contact our Experts Today
Learn how SPI Pharma can support your vaccine development. Contact us to discuss your developments with our experts